Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DV281 + Nivolumab in Advanced NSCLC
NCT03326752Phase 1Completed
- Sponsor
- Dynavax Technologies
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of DV281 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dynavax Technologies. Primary endpoints: Dose Limiting Toxicities and Safety and Preliminary Efficacy in Dose Expansion at 1 year. Started Sep 2017; status: completed.
02
Drugs
DV281
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03326752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326752.